Merck has signed a strategic collaboration agreement with Skyhawk Therapeutics to use its SkySTAR technology to develop drug candidates for patients with neurodegenerative diseases and cancer.
Biogen has signed a brace of collaborations to expand its central nervous system (CNS) pipeline, adding new candidates for Alzheimer’s, multiple sclerosis and other neurological diseases.